Targeted Therapies for Adrenocortical Carcinoma: IGF and Beyond
Michael J. Demeure . Kimberly J. Bussey . Lawrence S. Kirschner
Published online: 15 December 2011 C Springer Science+Business Media, LLC 2011
Abstract Standard chemotherapy for adrenocortical can- cer currently is under evaluation in the context of the recently completed FIRM-ACT evaluating the combina- tion of mitotane with either streptozocin or etoposide, cisplatin, and doxorubicin. New agents are eagerly sought by the ACC community that hopes to make progress against this deadly disease. Investigators have begun to dissect the molecular and genomic context of ACC with a goal of identifying potential novel therapeutic agents. One gene consistently overexpressed in ACC is insulin growth factor type 2. Targeting its receptor IGF1R has shown encouraging results in ACC cell lines and against murine xenografts. As a result, clinical trials to evaluate agents targeting the IGF1R have been done including mitotane and IMC-A12 (a monoclonal antibody) and the GALACCTIC trial that has just completed accrual to evaluate OSI-906, a small molecule IGF1R antagonist. On the horizon are other agents targeting other tyrosine kinases, including EGF and FGF, and novel strategies such as individualized tumor analysis to select treatment.
Keywords Adrenocortical cancer . Targeted therapy . IGF1R . Tyrosine Kinase inhibitors
M. J. Demeure . K. J. Bussey Clinical Translational Research Division, Translational Genomics Research Institute, Phoenix, AZ, USA
L. S. Kirschner Department of Endocrinology, Diabetes, and Metabolism, The Ohio State University, 420 West 12th Ave, TMRF 544, Columbus, OH 43210, USA e-mail: lawrence.kirschner@osumc.edu
Introduction
Although it is a relatively rare malignancy, adrenocortical cancer is a devastating diagnosis for those patients who are afflicted and for their families. Resectability is the prime determinant of prognosis. For those with disseminated disease, chemotherapy options are few and lack sufficient efficacy. Encouraging progress is starting to be made with the recent conclusion of accrual of both the FIRM-ACT and GALACCTIC trials focused on ACC. Both trials accrued ahead of schedule demonstrating the support the ACC community of researchers, clinicians, and patients toward finding new more effective treatments. In this review, we will review the current status of emerging potential treat- ments for ACC.
Targeting the IGF Signaling System
Molecular analyses of human cancers including adrenocor- tical cancer have identified perturbations in pathways regulating cell growth and survival. Current efforts to target the insulin-like growth factor type 2 (IGF2) receptor as a potential therapeutic strategy in ACC is the direct result of analysis by several groups of investigators that have shown consistently high expression of IGF2 in ACC. IGF2 effects are mediated through its receptor IGF1R resulting in activation of the PI3K/AKT/mTOR cascade and the RAS- MAPK pathway [1]. Several targeting strategies to block activation of IGF1R are being investigated. Monoclonal antibodies have been developed to the ligand or the receptor, such as cixutumumab (IMC-A12). At present, there is an ongoing randomized phase II trial comparing mitotane to mitotane and cixutumumab in patients with
adrenocortical cancer. A small molecular inhibitor of IGF1R, OSI-906, is also undergoing investigation in ACC. A phase III trial is ongoing comparing OSI-906 to best supportive care in patients with ACC that has progressed despite standard chemotherapy.
Targeting the IGF1R pathway is a rational strategy in adrenocortical cancer. In 2009, Barlaskar et al. demon- strated by expression array analysis that IGF2 was overexpressed in ACC compared to normal adrenal cells and benign adenomas [2]. They also showed that the combination of mitotane and IMC-A12 was synergistic in retarding the growth of murine xenografts of the H295 adrenal cortical cancer cell line. Features of the IMC-A12 monoclonal antibody relevant to its potential as a cancer therapeutic are that it is specific for the IGF1R receptor, it may induce antibody-dependent cellular cytotoxicity, it is administered intravenously, and while it has a relatively long half-life, it does not cross the blood- brain barrier [3, 4].
There is concern that anti-IGF1R monoclonal antibodies may induce compensatory activation of the epidermal growth factor and insulin receptors [5]. In studies of the small molecule IGF1R inhibitor OSI-906, inhibition of the IGF1R and the closely related insulin receptor (IR) resulted in enhanced inhibition of the AKT pathway, as demon- strated by reduction in phosphorylated AKT [5]. Class- specific features of the tyrosine kinase inhibitors are that because there is 95% homology in ATP binding sites of the IR and IGF1R, there may be an effect on glucose metabolism. Hyperglycemia has been observed in the clinical trials involving OSI-906. This agent is orally administered and may cross the blood-brain barrier [6]. At the Translational Genomics Research Institute (TGen), in vitro studies using the ACC cell lines, H295R and SW13, showed that OSI-906 is cytotoxic with IC50 levels of 0.59 and 32.5 uM, respectively [7]. In H295R murine xenografts, OSI-906 administered at 50 mg/kg showed 95% tumor growth inhibition at 28 days (personal communica- tion, OSI Oncology). In the phase I studies of OSI-906, 12 patients with ACC were enrolled. One of these patients had a partial response and four had stable disease by RECIST. The patient who exhibited a partial response is a 35-year- old woman with metastatic ACC to her lungs. She had been treated previously with mitotane, etoposide, doxorubicin, and cisplatin (mitotane-EDP) to achieve a partial response after 4 cycles. By 6 cycles, her tumor progressed. After 32 weeks, her primary right adrenal cancer and her lung metastases had decreased in size by 68%, using RECIST. Currently, the GALACCTIC phase III trial has completed its accrual goal of 135 patients. In this study, OSI-906 is being compared to best supportive care alone (i.e., placebo treatment) in a 2:1 randomization strategy to assess the potential efficacy of OSI-906 in patients whose ACC
tumors have progressed on standard chemotherapy with mitotane or mitotane-EDP. The primary endpoint of this study is overall survival. The accrual for the GALACCTIC study was less than 2 years, a rapid interval given the rarity of adrenocortical cancer, attesting to the dedication of the investigators, advocacy groups, and patients to make progress against this disease. The results of this trial are eagerly awaited.
Beyond the IGF1R
As outlined above, there is a wealth of information indicating that there is a strong molecular rationale for targeting the IGF1R as therapy for ACC. However, it is worth bearing in mind that treatment targeting other tyrosine kinases may also provide significant benefit. Like most cancers, ACC is a complex disease that results from multiple genetic hits affecting many signaling pathways. Thus, it is worth examining other known RTK systems in ACC with a goal to determine which may also be potential therapeutic targets, both from the viewpoint of being important causative agents in the cancer as well as being potentially druggable targets (Table 1).
EGFR
The epithelial growth factor receptor (EGFR, also known as ERBB1) is a tyrosine kinase whose extracellular domain binds and transduces the signal from EGF. There are three additional closely related family members, known as ERBB2, ERBB3, and ERBB4. EGFR family members are typical RTKs and comprise of extra- and intracellular portions linked by a single transmembrane domain. Signal- ing from this family of proteins occurs through ligand binding and the formation of homo- or heterodimers among family members. Although EGFR has ligand binding, dimerization, and tyrosine kinase domains, the same is not true for each of the family members. For example, the ERBB2 protein exists in an “open” configuration which does not require ligand binding. Also, ERBB3 lacks the kinase domain, so it can only transduce signals as a heterodimer [8]. The EGFR is expressed in >90% of tumors, although levels are similar to those observed in normal adrenal tissue [9, 10]. Surprisingly, EGF exhibits very low levels of expression in most tumors; however, the EGFR family can bind to other growth factors such as TGFx, which is expressed at high levels in ACC [10]. Because of these observations, a clinical trial was under- taken to assess the effectiveness of the EGFR TKI gefinitib as a single agent in ACC. This trial of 19 ACC patients did not show significant response [11]. Additionally, a small trial of another EGFR TKI erlotinib in combination with the
| Agent | Target(s) | Status | Comments |
|---|---|---|---|
| IMC-A12 | IGF1R | Active | Recruiting |
| OSI-906 | IGF1R | Active | Recruiting completed |
| Iressa | VEGFR | Completed | Unsuccessful |
| Axitinib | Multikinase (VEGFR/PDGFR/KIT) | Active | Active |
| Sunitinib | Multikinase (VEGFR/PDGFR/KIT) | Active | Recruiting completed; initial study unsuccessful |
| Sorafenib (+taxol) | Multikinase (RAF/VEGFR/PDGFR/KIT) | Unknown | |
| Vatalanib (+everolimus) | Multikinase (VEGFR/PDGFR/KIT) | Active | Trial for advanced solid tumors |
| Cabozantinib (XL184) | Multikinase (VEGFR/MET) | Active | No ACC trials; trials for other cancers (glioblastoma, lung CA, medullary thyroid CA, prostate CA) in various stages |
| Pertuzumab + erlotinib | EGFRs | Terminated | Extreme toxicity |
| Dovitinib | FGFRs | Active | No ACC trials; in trials for renal cell CA, hepatocellular CA, breast CA, endometrial CA |
| CWP232291 | Wnt | Not yet active | No ACC trials; in trial for AML |
Information for this table was collected from http://www.clinicaltrials.gov, accessed September 20, 2011. This table is meant to be illustrative of the discussion in the text and is not exhaustive
cytotoxic agent gemcitabine was carried out as salvage therapy in advanced ACC [12]. Unfortunately, this combi- nation of therapies produced minimal (if any) benefit and the trial was not expanded. No further trials have yet been undertaken. In retrospect, the poor success rate of gefinitib as a single agent is not surprising. First of all, this agent is very specific for the EGFR, such that signals transduced by other members of the receptor family or by receptor heterodimeri- zation are not blocked. There are some data to suggest that ERB2-ERB3 signaling pairs are the most potent growth stimulators in other types of cancer, so that Iressa would not have worked. Newer agents that may inhibit receptor dimerization (such as the mAb pertuzumab) may be more effective [8]. As discussed below, EGFR family members may be valuable tools in combination therapy for ACC.
FGFR
Aside from the IGF1R, members of the fibroblast growth factor receptor (FGFR) family appear to be among the most commonly overexpressed RTKs in ACC [13-16]. There are four members of the FGFR gene family, FGFR1-4 [17], and elevations in FGFR1 and/or FGFR4 have been observed in multiple studies. In one of these studies, upregulation of FGFR1 was shown to correlate with the malignant potential of the adrenal tumors [15]. Although the FGFR would seem to be a reasonable therapeutic target for ACC, clinical trials aimed at this pathway have not been undertaken. Therapeutic interest in the pathway has been stimulated by the observation that FGF signaling may also be activated by genetic translocations in multiple myeloma [18]. Part of the limitation on targeting FGF signaling has been the lack of agents targeted to this pathway. The small
molecule dovitinib (CHIR-258/TKI-25) was developed as an FGFR inhibitor. This agent, which has activity against multiple receptors including VEGFRs, PDGFR, and others, has shown preclinical activity in vitro and in vivo in cells expressing a variety of FGFR isoforms [19-21]. The agent was tolerated in a phase I trial for multiple myeloma [21] and is currently in clinical trials for renal cell CA, breast cancer, and multiple myeloma, although no results have yet been published. A second generated FGFR-targeted TKI, termed BGJ398, has now been developed and is currently in early phase I trials for advanced solid tumors (ClinicalTrails.gov NCT01004224). In addition to small molecule TKIs, a fusion protein consisting of the FGFR1 ligand-binding domain coupled to the IgG Fc region was developed as a decoy receptor to block FGF signaling. This molecule, known as FP-1039, had the anticipated ability to inhibit FGF-dependent activi- ties in preclinical models [22]. A phase I trial of this agent in advanced cancers demonstrated reasonable toler- ability and suggested some antitumor activity [23]. A phase II of this agent in endometrial cancers with known mutations in FGFR2 is underway (NCT01244438).
Wnt Inhibitors
The Wnt signaling system was initially discovered for its role in colon cancer associated with the inherited syndrome familial adenomatous polyposis (or adenomatous polyposis coli) [24, 25] and has since been determined to play a role in many types of cancer [26]. Investigation into adrenal cancer has suggested that activation of Wnt/ß-catenin signaling plays a role in adrenal neoplasia, including both benign and malignant tumors [27-30]. Interestingly, a
reassessment of microarray expression data has identified a subset of tumors with Wnt pathway mutations that appear to behave differently than other subclasses of tumors [31]. More work is still needed to understand this phenomenon. Nonetheless, there has been significant interest in develop- ing Wnt inhibitors for clinical use [32]. The most advanced of these agents is known as CWP232291 and is currently being developed by the Choongwae Pharma Corp. in South Korea. This agent has shown activity against multiple myeloma cells in preclinical models both in vitro and in vivo by promoting degradation of ß-catenin [33]. Although there is a lot of potential for antigrowth effects of agents targeted to this pathway, the widespread use of Wnt signaling for many cellular processes means that this research must proceed with caution due to concerns about significant toxicity [34].
Rationale for Combination Chemotherapy Strategies
To date, most clinical trials specifically targeted to ACC have focused on the use of single TKIs (Table 1). Although this information is valuable in establishing a baseline for therapeutic efficacy, this type of treatment seems destined to provide only modest benefit to patients. A more fruitful approach may be the use of multiple agents, a practice well understood not only from oncology but also in microbiol- ogy where multiagent therapy is the norm for difficult cases. This type of rationale is based on multiple factors. First, multiple signaling pathways typically are involved in cancer, such that (as discussed above) single-agent strate- gies may just shift the dominant signaling pathways to those that are not blocked. Second, resistance to single agents may occur by mutation of the target kinase, gene amplification, or upregulation of alternate pathways [35]. This latter effect could be blocked by using targeted therapies against these emerging changes. Third, strategies aimed at targeting multiple signaling pathways may benefit from therapeutic synergism and be significantly more effective than single agents used in sequential fashion. Finally, kinase inhibition may affect other factors contrib- uting to tumor growth and spread, including those in the microenvironment.
In regard to synergy, there are well-documented inter- actions between the IGF1R and EGFR signaling pathways [5, 36, 37]. It has been demonstrated that tumors that are sensitive to IGF1R inhibitors rapidly upregulate signaling through the EGFR system as a means to resistance [38], and the converse is also true [37]. For this reason, combining agents targeting both of these pathways would seem a rational approach likely to enhance effectiveness of the agents. The interaction of the IGF and EGF signaling pathways has been demonstrated in multiple preclinical systems, and therapeutic cooperativity has been confirmed,
regardless of whether antibodies or small molecule TKIs have been used [5, 36, 37, 39, 40]. Recently a clinical trial of the IGF1R-targeting OSI-906 and the EGFR-targeting erlotinib (originally OSI-774) is already underway. Phase I studies have shown that there is moderate but manageable toxicity of the combination therapy, and an expansion cohort using nonsmall cell lung cancer (NSCLC) patients was planned along with an upcoming phase II effort. This study indicates the feasibility of combination therapy and should lead to new and exciting trials in this area. Other combinations that may be worthy of consideration would be joint IGF1R/FGFR blockade.
Using TKIs in Novel Treatment Paradigms
Antiangiogenic Agents
Since the groundbreaking work of Folkman [41], there has been recognition that tumors require the development of new vessels and that this requirement presents a therapeutic opportunity [42]. Angiogenesis is driven primarily by signaling through the vascular epithelial growth factor (VEGF) pathway, and there are three VEGF receptors, VEGFR1 (Flt1), VEGFR2 (Flk1/KDR), and VEGFR3 (Flt4). VEGFR2 is thought to be the major mediator of blood vessel growth, although the others may also play roles. There is good in vivo evidence in model systems that targeting the vasculature is effective, including the obser- vation that pretreatment with anti-VE-cadherin-linked agents to “normalize” the tumor vascular enhances subse- quent delivery of cytotoxic chemotherapy [43]. The first antiangiogenic therapy to be approved was the monoclonal antibody bevacizumab, which targets the VEGFR. Initial studies demonstrated modest effectiveness against colon cancer [44], and it was subsequently approved for treatment of NSCLC and breast cancer as well [45]. Recent data have shed some doubt on the usefulness of the agent for breast cancer, and a reevaluation of this therapy is currently underway [46]. More recent agents that target the VEGFRs include the multikinase inhibitors sorafenib and sunitinib, which target these pathways among others. A trial of sunitinib as a single agent for ACC was not successful, although the trial was confounded by the fact that adequate serum levels of the drug were rarely obtained [47]. A second signaling system that seems to be important for angiogeneisis involves MET (hepatocyte growth factor) and its receptor HGFR. MET is typically expressed at high levels in the tumor microenvironment, and this signaling system appears to be an important secondary pathway for angiogenesis. A switch to MET-HGFR may be an impor- tant mechanism that accounts for resistance of tumors to therapies targeted to the VEGFRs, such that combination therapy has been shown to be effective in preclinical
models [48]. Intriguingly, XL-184, a multikinase inhibitor currently in clinical trials, targets both VEGFR and HGF, making it an agent with potential promise in this area.
Antimetastasis Agents
Because metastatic disease is a common cause of morbidity and mortality in ACC, the emerging field of metastasis suppression may be highly relevant to the therapy of ACC tumors. Although a thorough review is the beyond the scope of this paper, many excellent reviews on this topic have been published [49-52]. In terms of therapeutic interventions, an intriguing target is stromal-derived factor 1 (SDF1, also known as CXCL12) and its receptor CXCR4. SDF1 is a secreted cytokine whose levels are increased by mutant forms of p53 [53] such as may be observed in ACC tumors [54]. SDF1-CXCR4 interactions seem to be important for homing of tumor cells to appropriate metastatic niches. This same process is involved in immune cell homing. The agent AMD3100 is a clinical agent in use that works through this mechanism. By blocking SDF1- CXCR4 interactions, it causes enhanced mobilization of bone marrow cells, which can then be used for bone marrow transplantation. Whether this could be used to block metastatic seeding is an avenue that may be worth pursuing.
Individualized Treatments
In addition to exploring the novel agents described above, investigators and patients are now considering future areas of study. One area of exciting research proposes to identify individualized treatment strategies which will allow selec- tion of agent or combinations of agents or dosing schedules that will be the most effective for each patient. In order to better select treatment strategies for each particular patient, one must develop better markers of either drug sensitivity or resistance based on tumor biology. For example, investigators including the group in Wurzburg have shown that a marker of drug resistance, ERCC1, can predict a likelihood of failure of treatment with platinum agents in ACC [55]. Standard chemotherapy for ACC is currently the regimen of etoposide, doxorubicin, and cisplatin plus mitotane as proposed by the Italian group [56]. This regimen, in their phase II trial, was associated with a 49% response rate. It is, however, a fairly rigorous regimen associated with significant toxicity. The questions regarding this regimen remaining include whether the regimens dosing schedule and component agents should be altered based on the patient’s individual tumor characteristics. As demonstrated by the Wurzburg group, if tumor ERCC1 levels are high, then one is unlikely to have a response to platinum agents, so for these patients should cisplatin be
omitted? Although this hypothesis has not been tested, the current literature at least suggests one should definitely include cisplatinum in the chemotherapy regimen for patients with ACC tumors expressing low levels of ERCC1. Our expression profiling of patient tumors shows that in ACC, there is overexpression of the TOP2A and low expression of the multidrug resistance gene MDR1 which should predict a favorable tumor response to treatment with doxorubicin. Further analysis, however, shows that there are three subsets with distinct tumor profiles regarding expression of the TOP2A and MDR1 genes. In one subset, TOP2A is low, so it seems unlikely that treatment with the drug targeting this gene would be effective. In another subset with increased TOP2A expression, where one might predict that doxorubicin may be highly effective, if MDR1 expression is also increased, one might predict then that the beneficial effect of the agent would be mitigated. Ideally, one would select a patient with high TOP2A and low MDR1 levels in their ACC tumor samples to treat with doxorubicin. Although this strategy holds promise, verifi- cation using in vitro drug testing or studying tumor response in vivo using mouse xenografts will likely be an important bridge between molecular analysis and therapeu- tic selection in individual patients.
Recent work in the Demeure and Bussey lab has also highlighted preclinical evidence for nanoparticle-bound paclitaxel (nab-paclitaxel) to be investigated clinically in ACC [57]. The therapeutic target for nab-paclitaxel secreted protein acidic rich in cysteine was overexpressed 1.5-fold by microarray in ACC (Bussey and Demeure, unpublished data). Nab-paclitaxel is approved in the USA for the treatment of breast cancer. Knowledge mining of our expression array data set showed strong concordance with published breast cancer expression data sets. Previous cell line work had suggested in vitro efficacy in the H295 ACC cell line [58] prompting efforts to pursue this lead. In these studies, efficacy was observed in vitro and in vivo with murine xenografts using either the H295R or SW13 ACC cell lines (Bussey and Demeure, unpublished data).
In addition to expression array profiling, one can examine tumors by comparative genomic hybridization (CGH) to identify genomic aberrations that may give insights into potential treatments. In our profiling of ACC tumors, we found that some genomic aberrations could be correlated to a relatively poor prognosis [59]. In some cases, the detection of focal genomic aberrations could expose indication of a therapeutic vulnerability or suggest resistance to agents. For example, in one ACC, our group found a focal amplicon in BRIP1 (BRCA1 interacting protein C-terminal helicase), a gene which in some cases be a target of germline cancer-inducing mutations (Fig. 1). BRIP1 is a part of the Fanconi anemia pathway involved in the repair of DNA double-stranded breaks by homologous
17: 56350789-56010789, 1.65 Mb
BRIP1
ScaberPol
. 4
?
.
..
. .
··
…
#
:
C
.
56.31%
56.616
56.9 Mb
57.1 Mb
$7.4Mb
57.7 Mb
50.0
17
-
7
00132
0
www
P
a
”
1
-
3
4
5
€
4
9
10
14
13
?
19
22
X
recombination. BRIP1 may be a target of germline cancer- inducing mutations; one hypothesis is that amplification of this gene provides a selective advantage to this tumor. Increased expression of FANCJ (BRIP1) has been detected in invasive high-grade breast cancers and is associated with a relatively poor prognosis [60]. Inactivation of BRIP1 through LOH and mutation with the resulting loss of BRCA1- BRIP1 interaction results in impaired DNA repair, checkpoint control, and decreased tolerance to DNA damage. Conse- quently, one could surmise that this amplicon may signal that this patient’s tumor is resistant to DNA damaging agents such as cisplatin, mitomycin C, or a PARP inhibitor.
Perhaps in the not very far away future is the ultimate form of personalized cancer treatment based on whole genome sequence (WGS) analysis. The cost of NextGen sequencing has been dropping rapidly, and the analytic tools required to allow routine clinical use do not seem to be far away. Once can foresee a time where one can envision a scenario in which a patient has a biopsy of their ACC done for WGS. A team of consisting of oncologists, bioinformaticians, systems biolo- gists, and pharmacologists review that data and design a treatment regimen targeting the genomic context of the individual patient’s cancer. In this way information becomes the key therapeutic asset, in a way never before seen.
Summary and Future Directions
The wealth of molecular data available about the patho- genic changes that occur in ACC has enabled the
panel depicts a further magnification view of the amplification in chromosome 17q between the loci q22.2 and q23.2 demonstrating a very focal aberration, as called by the Agilent detection software. This aberration contains only the BRIP1 gene, as shown by the bar below the probes
development of strategies that may be more effective for treating these tumors. There is currently excitement in the field regarding the use of IGF1R inhibitors, and the results of the GALACCTIC trial (OSI-906 IGF1R TKI) and other similar trials should be available shortly. While the ACC community eagerly awaits the final conclusions of the FIRM-ACT and GALACCTIC clinical studies, all are cognizant that ACC has not been cured. While new agents including IGF1R inhibitors are on the horizon, it seems unlikely that single-agent regimens will provide the most effective treatment for an aggressive tumor like ACC. There is rationale for the involvement of other signaling path- ways, including the EGF and FGF families of ligands and receptors that may have direct antitumor effects. There is also likely a role of other therapies targeting other process of the cancer pathway, including angiogenesis and other aspects of the microenvironment. As these agents come online for clinical use, it will be important to remain vigilant regarding side effects, as patients with hormone- secreting tumors may be at increased risk for complications [61, 62]. For example, VEGFR-targeted agents caused hypertension and decreased wound healing, adverse effects that may be augmented in patients with cortisol-secreting ACCs. Novel genomic technologies offer the promise of individually targeted treatments. A greater understanding of the molecular oncogenesis afforded by the application of genomic technologies including whole genome sequencing should speed progress toward more effective treatments. To make progress in the field, the involvement of large multinational consortia is needed to evaluate combinations
of agents or therapeutic strategies in clinical trials. It is particularly encouraging that the ACC community of patients, physicians, and advocates has demonstrated that clinical trials in ACC can be accrued successfully and ahead of schedule.
Conflict of Interest Statement The authors declare that they have no conflict of interest.
References
1. Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8:915-928
2. Barlaskar FM, Spalding AC, Heaton JH et al (2009) Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. J Clin Endocrinol Metab 94:204-212
3. Imai K, Takaoka A (2006) Comparing antibody and small- molecule therapies for cancer. Nat Rev Cancer 6:714-727
4. Rodon J, DeSantos V, Ferry RJ, Kurzrock R (2008) Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther 7:2575-2588
5. Buck E, Eyzaguirre A, Rosenfeld-Franklin M et al (2008) Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res 68:8322-8332
6. Boyd DB (2003) Insulin and cancer. Integr Cancer Ther 2:315-329
7. Dastrup E, Demeure MJ, Bussey KJ. Adrenocortical carcinoma cell lines are sensitive to compounds targeting the G2/M transition [abstract]. In Proceedings of the 101st Annual Meeting of the American Association for Cancer Research. Washington. AACR; 2010:Abstract nr 3672
8. Baselga J, Swain SM (2009) Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9:463-475
9. Kamio T, Shigematsu K, Sou H, Kawai K, Tsuchiyama H (1990) Immunohistochemical expression of epidermal growth factor receptors in human adrenocortical carcinoma. Hum Pathol 21:277-282
10. Sasano H, Suzuki T, Shizawa S, Kato K, Nagura H (1994) Transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor expression in normal and diseased human adrenal cortex by immunohistochemistry and in situ hybridization. Mod Pathol 7:741-746
11. Samnotra V, Vassilopoulou-Sellin R, Fojo A et al (2007) A phase II trial of gefitinib monotherapy in patients with unresectable adrenocortical carcinoma (ACC). J Clin Oncol 25:15527
12. Quinkler M, Hahner S, Wortmann S et al (2008) Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcita- bine. J Clin Endocrinol Metab 93:2057-2062
13. de Fraipont F, El Atifi M, Cherradi N et al (2005) Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy. J Clin Endocrinol Metab 90:1819-1829
14. Giordano TJ, Thomas DG, Kuick R et al (2003) Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol 162:521-531
15. Slater EP, Diehl SM, Langer P et al (2006) Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors. Eur J Endocrinol 154:587-598
16. West AN, Neale GA, Pounds S et al (2007) Gene expression profiling of childhood adrenocortical tumors. Cancer Res 67:600-608
17. Turner N, Grose R (2010) Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10:116-129
18. Trudel S, Li ZH, Wei E et al (2005) CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 105:2941-2948
19. Xin X, Abrams TJ, Hollenbach PW et al (2006) CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice. Clin Cancer Res 12:4908-4915
20. Chase A, Grand FH, Cross NC (2007) Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. Blood 110:3729-3734
21. Loilome W, Joshi AD, ap Rhys CM et al (2009) Glioblastoma cell growth is suppressed by disruption of fibroblast growth factor pathway signaling. J Neurooncol 94:359-366
22. Zhang H, Masuoka L, Baker K et al (2007) FP-1039 (FGFR1:Fc), A Soluble FGFR1 receptor antagonist, inhibits tumor growth and angiogenesis. In AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics Discovery, Biology and Clinical Applications. San Francisco, CA .; 2007
23. Tolcher A, Papadopoulos K, Agnew J et al (2009) Preliminary results of a phase 1 study of FP-1039 (FGFR1:Fc), a novel antagonist of multiple fibroblast growth factor (FGF) ligands, in patients with advanced malignancies. Mol Cancer Ther 8:A103
24. Leach FS, Nicolaides NC, Papadopoulos N et al (1993) Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 75:1215-1225
25. Fishel R, Lescoe MK, Rao MR et al (1993) The human mutator gene homolog MSH2 and its association with hereditary non- polyposis colon cancer. Cell 75:1027-1038
26. Reya T, Clevers H (2005) Wnt signalling in stem cells and cancer. Nature 434:843-850
27. Tadjine M, Lampron A, Ouadi L, Bourdeau I (2008) Frequent mutations of beta-catenin gene in sporadic secreting adrenocorti- cal adenomas. Clin Endocrinol (Oxf) 68:264-270
28. Gaujoux S, Tissier F, Groussin L et al (2008) Wnt/beta-catenin and 3’,5’-cyclic adenosine 5’-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors. J Clin Endocrinol Metab 93:4135-4140
29. Tissier F, Cavard C, Groussin L et al (2005) Mutations of beta- catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res 65:7622-7627
30. Seki M, Tanaka K, Kikuchi-Yanoshita R et al (1992) Loss of normal allele of the APC gene in an adrenocortical carcinoma from a patient with familial adenomatous polyposis. Hum Genet 89:298-300
31. de Reynies A, Assie G, Rickman DS et al (2009) Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol 27:1108-1115
32. Curtin JC, Lorenzi MV (2010) Drug discovery approaches to target Wnt signaling in cancer stem cells. Oncotarget 1:563-577
33. Cha JY, Jung J-E, Lee K-H et al (2010) Anti-tumor activity of novel small molecule Wnt signaling inhibitor, CWP232291, in multiple myeloma. In 52nd American Society for Hematology Annual Meeting. Orlando, FL:3038
34. Garber K (2009) Drugging the Wnt pathway: problems and progress. J Natl Cancer Inst 101:548-550
35. Sierra JR, Cepero V, Giordano S (2010) Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol Cancer 9:75
36. Cunningham MP, Thomas H, Marks C et al (2008) Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells. Int J Oncol 33:1107-1113
37. Jin Q, Esteva FJ (2008) Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. J Mammary Gland Biol Neoplasia 13:485-498
38. Huang F, Greer A, Hurlburt W et al (2009) The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/ HER2 inhibitors. Cancer Res 69:161-170
39. Takahari D, Yamada Y, Okita NT et al (2009) Relationships of insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer. Oncology 76:42-48
40. Barnes CJ, Ohshiro K, Rayala SK, El-Naggar AK, Kumar R (2007) Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res 13:4291-4299
41. Folkman J (1975) Tumor angiogenesis: a possible control point in tumor growth. Ann Intern Med 82:96-100
42. Zetter BR (2008) The scientific contributions of M. Judah Folkman to cancer research. Nat Rev Cancer 8:647-654
43. Escorcia FE, Henke E, McDevitt MR et al (2010) Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors. Cancer Res 70:9277-9286
44. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizu- mab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342
45. Bergers G, Hanahan D (2008) Modes of resistance to anti- angiogenic therapy. Nat Rev Cancer 8:592-603
46. D’Agostino RB (2011) Changing end points in breast-cancer drug approval-the Avastin story. N Engl J Med 365(2):e2
47. Quinkler M, Kroiss M, Hahner S et al (2011) Sunitinib in refractory adrenocortical carcinoma: results of a phase II trial. Endocr Abstr (in press)
48. Shojaei F, Lee JH, Simmons BH et al (2010) HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res 70:10090-10100
49. Smith SC, Theodorescu D (2009) Learning therapeutic lessons from metastasis suppressor proteins. Nat Rev Cancer 9:253-264
50. Cook LM, Hurst DR, Welch DR (2011) Metastasis suppressors and the tumor microenvironment. Semin Cancer Biol 21:113-122
51. Hurst DR, Welch DR (2011) Metastasis suppressor genes at the interface between the environment and tumor cell growth. Int Rev Cell Mol Biol 286:107-180
52. Iiizumi M, Liu W, Pai SK, Furuta E, Watabe K (2008) Drug development against metastasis-related genes and their path- ways: a rationale for cancer therapy. Biochim Biophys Acta 1786:87-104
53. Addadi Y, Moskovits N, Granot D et al (2010) p53 status in stromal fibroblasts modulates tumor growth in an SDF1- dependent manner. Cancer Res 70:9650-9658
54. Sidhu S, Martin E, Gicquel C et al (2005) Mutation and methylation analysis of TP53 in adrenal carcinogenesis. Eur J Surg Oncol 31:549-554
55. Ronchi CL, Sbiera S, Kraus L et al (2009) Expression of excision repair cross complementing group 1 and prognosis in adrenocor- tical carcinoma patients treated with platinum-based chemothera- py. Endocr Relat Cancer 16:907-918
56. Berruti A, Terzolo M, Sperone P et al (2005) Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer 12:657-666
57. Demeure MJ, Stephan E, Sinari S et al (2011) Preclinical investigation of nanoparticle albumin-bound paclitaxel as a potential treatment for adrenocortical cancer. Ann Surg (in press)
58. Fallo F, Pilon C, Barzon L et al (1998) Paclitaxel is an effective antiproliferative agent on the human NCI-H295 adrenocortical carcinoma cell line. Chemotherapy 44:129-134
59. Stephan EA, Chung TH, Grant CS et al (2008) Adrenocortical carcinoma survival rates correlated to genomic copy number variants. Mol Cancer Ther 7:425-431
60. Eelen G, Vanden Bempt I, Verlinden L et al (2008) Expression of the BRCA1-interacting protein Brip1/BACH1/FANCJ is driven by E2F and correlates with human breast cancer malignancy. Oncogene 27:4233-4241
61. Ye L, Santarpia L, Gagel RF (2010) The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors. Endocr Rev 31:578-599
62. Chen HX, Cleck JN (2009) Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 6:465-477